MediWound (Nasdaq: MDWD) is a biotechnology company that manufactures and commercializes novel, cost effective, biotherapeutic solutions for tissue repair and regeneration.

MediWound leverages its enzymatic technology platform, focused on next-generation bio active therapies for burn, wound care and tissue repair.

NexoBrid^TM, MediWound’s lead product, is a commercial, orphan biological product for eschar removal of severe thermal burns.

Nexobrid is currently marketed in the European Union as well as in other international markets and is at registration stage in the U.S. NexoBrid is supported by the U.S. Biomedical Advanced Research and Development Authority (BARDA). The company submitted to the FDA the Biologics License Application (BLA) for NexoBrid^TM with a PDUFA target action date set for January 1, 2023.

EscharEx^®, MediWound’s next-generation bioactive topical therapy for debridement of chronic and hard-to-heal wounds, is in advanced development stages.